文献速递肝病

综述:布加综合征诊断与管理的多学科方法

Review article: a multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome.
PubMed 文献 · Aliment Pharmacol Ther · 2019-03-03

布加综合征(BCS)是肝静脉流出道梗阻导致的罕见致死性疾病。本文通过检索Medline、PubMed和EMBASE数据库综述其病理生理、病因、诊断、管理与随访。非侵入性影像通常可确诊,阶梯式管理策略(抗凝、经皮血管重建、TIPS、肝移植)使5年生存率近90%,长期结局受血液系统疾病和肝细胞癌影响。

要点

  • BCS应在大任何急性或慢性肝病患者中排除,非侵入性影像通常可提供诊断。
  • 欧洲患者中骨髓增殖性肿瘤占35%-50%,常与JAK2-V617F突变相关。
  • 阶梯式管理策略提供近90%的5年生存率,长期结局受血液系统疾病和肝细胞癌影响。

核心结论

  • 随着新治疗策略的出现和对BCS理解的提高,过去三十年中这种罕见疾病的结局已有所改善。
  • 潜在的血液系统疾病可能是结局的主要决定因素。

研究设计与样本

  • 通过使用Medline、PubMed和EMBASE数据库对近期文献进行分析的综述。

主要发现

  • 原发性BCS通常由血栓形成引起,进一步分为「经典BCS」型(梗阻发生在肝静脉内)和「肝腔静脉BCS」(涉及下腔静脉肝内/肝上段血栓形成)。
  • BCS患者常合并多种促血栓风险因素。
  • 病因和表现因西方国家与某些亚洲国家而异。
  • 欧洲患者中骨髓增殖性肿瘤占35%-50%,通常与JAK2-V617F突变相关。
  • 临床表现多样,任何急性或慢性肝病患者均应排除BCS。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Budd-Chiari syndrome (BCS) is a rare but fatal disease caused by obstruction in the hepatic venous outflow tract. AIM: To provide an update of the pathophysiology, aetiology, diagnosis, management and follow-up of BCS. METHODS: Analysis of recent literature by using Medline, PubMed and EMBASE databases. RESULTS: Primary BCS is usually caused by thrombosis and is further classified into "classical BCS" type where obstruction occurs within the hepatic vein and "hepatic vena cava BCS" which involves thrombosis of the intra/suprahepatic portion of the inferior vena cava (IVC). BCS patients often have a combination of prothrombotic risk factors. Aetiology and presentation differ between Western and certain Asian countries. Myeloproliferative neoplasms are present in 35%-50% of European patients and are usually associated with the JAK2-V617F mutation. Clinical presentation is diverse and BCS should be excluded in any patient with acute or chronic liver disease. Non-invasive imaging (Doppler ultrasound, computed tomography, or magnetic resonance imaging) usually provides the diagnosis. Liver biopsy should be obtained if small vessel BCS is suspected. Stepwise management strategy includes anticoagulation, treatment of identified prothrombotic risk factors, percutaneous revascularisation and transjugular intrahepatic portosystemic stent shunt to re-establish hepatic venous drainage, and liver transplantation in unresponsive patients. This strategy provides a 5-year survival rate of nearly 90%. Long-term outcome is influenced by any underlying haematological condition and development of hepatocellular carcinoma. CONCLUSIONS: With the advent of newer treatment strategies and improved understanding of BCS, outcomes in this rare disease have improved over the last three decades. An underlying haematological disorder can be the major determinant of outcome.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Khan F, Armstrong MJ, Mehrzad H, et al. Review article: a multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome. Aliment Pharmacol Ther. 2019. PMID: 30828850. doi:10.1111/apt.15149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。